

## Molecular alterations induced in drug-resistant cells

Maja Osmak

*Instiut Rudjer Bošković, Zagreb, Croatia*

---

*The major obstacle to the ultimate success in cancer therapy is the ability of tumor cells to develop resistance to anticancer drugs. Several molecular mechanisms have been suggested to be involved in drug-resistance: a) decrease in the intracellular drug accumulation (increased activity of membrane transporters such as P-glycoprotein or multidrug-resistance-associated protein), b) changes in intracellular detoxification system (increased concentrations of glutathione or metallothioneins, or increased activity of related enzymes), c) alteration in nuclear enzymes (enhanced DNA repair and/or better tolerance of DNA damage, decreased activity of topoisomerases), d) altered expression of oncogenes (inducing increased level of protective molecules in cells or the inhibition of apoptosis). Drug resistance is a multifactorial phenomenon. The complexity of molecular alterations in drug-resistant cells is and will stay the main problem for the successful treatment of cancer.*

*Key words: drug resistance, tumor cells; cancer chemotherapy*

---

### Introduction

Chemotherapy is one of the proven strategies against malignant tumors, especially if the lesions are spread systematically. In many patients, first regimens are successful in reducing tumor size and are sometimes even able to eliminate all clinically detectable tumor masses. But most often, the successful treatments are relatively short lasting. In a vast majority, a certain number of tumor cells will survive and thus become a source of recurrent disease.

Chemotherapy of cancer may fail for vari-

ous reasons. Among these, drug resistance is the most important one. This phenomenon was first observed by Sidney Farber (who introduced chemotherapy into cancer treatment) in 1948.<sup>1</sup> Almost fifty years later the molecular mechanisms involved in this process have been unravelled.

Resistance may be primary (intrinsic): the tumor cells do not respond from the start. Drug-resistance may be secondary (acquired): under the selection pressure of cytotoxic drugs tumor cells are able to develop certain mechanisms which render them resistant to these drugs. The tumor initially responds to therapy, but tumor growth resumes and the patient relapses.

Knowledge regarding the genetic nature and biochemical nature of drug resistance

---

Correspondence to: Maja Osmak Ph.D., Rudjer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia. Tel: +385 1 456 11 45; Fax: +385 1 456 11 77; E-mail: osmak@olimp.irb.hr

has been derived largely from cellular systems. By step-wise increase in the drug dose, highly resistant cell lines can be obtained. The mechanisms of drug resistance can be defined by comparing the biochemical and biological characteristics of parental and resistant cells.

A search for the cause or causes of drug resistance mechanisms has been occupying the attention of cancer researchers for more than four decades. Today it is known that several molecular mechanisms can be involved in drug-resistance. The most important one will be presented in this review.

**Reduced intracellular accumulation:  
transport proteins**

A broad spectrum resistance to cytotoxic drugs, termed multidrug resistance (MDR),

involves simultaneous resistance to a wide array of natural, semisynthetic and synthetic compounds. The most common of them are shown in Table 1. They do not have similar structure or the same cytotoxic intracellular target, but are amphipathic and are preferentially soluble in lipid.

Multidrug resistance is caused by overexpression of a 170 kDa plasma membrane - associated glycoprotein (P-glycoprotein, Pgp; Table 1). It is an energy dependent efflux pump that decreases intracellular drug accumulation.<sup>2-4</sup> Pgps are coded by *MDR* gene family. The number of members varies between species. Human possess two *MDR* genes, *MDR1* and *MDR2*. Of these, only *MDR1* can confer a drug resistance phenotype.<sup>5</sup> Multidrug resistant cells, particularly those which display high levels of resistance, often possess an increased copy number of the *MDR1* gene.<sup>2,4</sup>

It was noted that Pgp bore a remarkable

**Table 1.** Characteristics of transport proteins: P-glycoprotein and MRP protein

Name	P-glycoprotein (Pgp)	MRP (multidrug resistance-associated protein)
Encoded by	<i>MDR1</i> gene	<i>MRP</i> gene
Mol. weight	170 kDa	190 kDa
Length	4.5 kb mRNA	6.5 kb mRNA
Number of amino acid	1268	1531
Discovered in	1970 year	1992 year
Resistance to	Anthracyclines, Vinca alkaloids, Podophyllotoxins, Colchicine, paclitaxel	Anthracyclines, Vinca alkaloids Arsenic and antimony-centered oxyanions
Normal tissues distribution (high levels)	Adrenal gland, kidney, liver, large intestine, pancreas, bile duct, lung, breast, prostate, gravid uterus	Testes, skeletal muscle, heart, kidney, lung
Tumor tissues distribution	Colonic, renal, hepatoma, adrenocortical, phaeochromocytoma	Leukemias ( acute myeloid, chronic lymphocytic, acute myeloid, B-chronic lymphocytic),lung (NSCLC), anaplastic thyroid, neuroblastoma
Functions	Transport of xenobiotics Transport of hormones	Transport of leukotriene Transport of GSH-conjugates Transport of heavy metal oxyanions "MOAT" (multispecific organic anion transporter)

According to references <sup>2-4</sup> and <sup>9</sup>

structural similarity to bacterial transport proteins, particularly those transporting haemolysin.<sup>6</sup> Presumably, in evolutionary terms, it represents a highly conserved component of the cell. P-glycoprotein is detectable at a high concentration in certain normal tissues (Table 1). The disposition of the Pgp on the luminal surface of kidney brush border, on the mucosal surface of the large intestine, and on the bile canalicular surface of hepatocytes, indicates a normal role in transport and/or protection against exogenous toxins. High levels of Pgp were found in different tumors as well, specially in those arising from the normal tissue with a high Pgp level.<sup>2-4</sup>

Pgp overexpression has been associated with multidrug resistance in many drug-selected cell lines.<sup>7</sup> The final evidence that *MDR* gene is involved in multidrug resistance came from transfection studies: *MDR1* gene inserted into retroviral expression vector confers a complete multidrug resistance phenotype.<sup>5</sup>

Recently, another member of the ATP-binding cassette transporter superfamily was isolated from non-Pgp small cell lung carcinoma cells, multidrug resistance-associated protein (MRP).<sup>8</sup> It also lowers intracellular drug accumulation, conferring a pattern of drug resistance similar to that of the resistance-conferring Pgps.<sup>9</sup> However, there may be some differences. For example, MRP confers only low resistance to paclitaxel and colchicine, which are reported among the best "substrates" for Pgp. Another notable difference is the ability of MRP to confer low resistance to arsenic and antimony-centered oxyanions. The characteristics of this protein are given in Table 1.

MRP has been identified in non-Pgp multidrug resistant cell lines from a variety of tumor types.<sup>9</sup> Transfection of an MRP expression vector into HeLa cells demonstrated conclusively that the protein conferred resistance to drugs.<sup>10</sup>

Some recent observations suggest that elevated MRP expression may occur prior to *MDR*.<sup>11,12</sup>

### Decreased drug uptake

Decreased intracellular drug accumulation may occur due to decreased drug uptake, for drugs that enter the cells by the help of a cellular transport system. Loss or inactivation of this transport system may cause drug resistance, as it was observed for melphalan,<sup>13</sup> methotrexate<sup>14</sup> or cisplatin.<sup>15</sup>

### Glutathione

Glutathione (GSH) is a simple tripeptide that contributes to more than 90% of intracellular non-protein sulphydryl compounds.<sup>16,17</sup> It is present in virtually all eucariotic cells. It is also synthesized by tumors, some of which exhibit high cellular levels of glutathione and high capacity for the synthesis of glutathione.

Glutathione plays an important role in cellular metabolism and in the protection of cells against free radicals induced oxidant injury (Table 2). It has been implicated in cell resistance to a number of cytotoxic drugs, particularly to alkylating agents and cisplatin.<sup>18-22</sup> There are a number of potential mechanisms by which GSH may affect cellular response to cytostatics. These include conjugation of electrophilic compounds, frequently catalyzed by the glutathione S-transferases (GST). In addition, GSH can detoxify oxygen-induced free radicals and organoperoxides using GSH-peroxidases.<sup>23</sup>

GSH may participate in the resistant phenotype in two ways. In cytoplasm it may bind electrophilic compounds, thus making them less dangerous. In nucleus, GSH may support the repair of the damage induced in DNA: by maintaining functional repair

**Table 2.** Functions of glutathione in metabolism and immune response

Functions	Antioxidant Conjugation with different compounds (exogenous, the products of metabolism) Amino acid transport Support of primary antibody response Regulation of T-lymphocyte proliferation Co-enzyme for multiple enzymatic reactions Thiol-disulfide exchange in protein synthesis and degradation DNA precursor synthesis Enzyme activation Regulation of microtubule formation Negative control of NF-κB activation
Deficiency	Increased sensitivity to irradiation and different toxic compounds Oxidant stress Cataract formation Impaired function of both T and B lymphocyte function and immune function in general

According to references <sup>16</sup> and <sup>17</sup>

enzymes or by maintaining deoxyribonucleotide triphosphate pool size.<sup>24</sup>


An argument for the potential role of GSH in resistance is based on the observation that the toxicity of many cytotoxic agents can be increased by lowering cellular GSH (as by adding specific inhibitor of GSH synthesis-buthionine sulfoximine).<sup>25,26</sup>

**Glutathione S-transferases**

Glutathione S-transferases (GST) are an important part of the Phase II detoxification system that metabolizes many lipophilic drugs and other foreign compounds, including anticancer drugs.<sup>27-29</sup> The overall result of this system is the conversion of lipophilic chemicals to more polar derivatives, thus facilitating their inactivation and elimination. GST are abundant and together may constitute up to about 5 % of soluble cellular protein. Their

importance supports the finding that they perform specific detoxification, structural and transport function in many phila: from bacteria to humans.

GST catalyze direct coupling of GSH to electrophilic drugs, thus making a less toxic and more readily excreted metabolic compound.



**Figure 1.** Conjugation reaction catalyzed by GSTs

Further, they may exhibit ligand binding function, by non-covalent binding of non-substrate hydrophobic ligands (such as heme, bilirubin, some steroids, and some lipophilic cytostatics).<sup>27-29</sup>

The diverse biological functions of GSH/GST system are mediated by multiple GST enzymes. The genome of most species encode several different isoenzymes of GSTs. In eucaryotic cells, there are five classes of GST. Four are found in cytosol, while the fifth class, the microsomal GST, is found primarily in the hepatic endoplasmic reticulum.

The microsomal GST are functional trimers with molecular weights of 17 kDa. Cytosol GST are both mono- and heterodimeric complexes formed of GST subunits that range in size from 23 to 28 kDa. The classification of the cytosolic GST into alpha, pi and mu, and recently identified theta classes was originally based on physical and catalytic properties. Among them, GST pi was found at elevated levels in many tumor tissues relative to matched normal tissues.<sup>30,31</sup>

Several anticancer drugs have been definitively identified as GST substrates (Table 3). Therefore, it is not surprising that elevated levels of GST were found in cells resistant to some of these drugs like cisplatin, doxorubicin, melphalan etc.<sup>27-29</sup>

The final confirmation of GST involvement in drug resistance came from the transfection experiments.<sup>32</sup> The tranfection with

**Table 3.** Anticancer drugs: substrates for glutathione S-transferases

Direct evidence for involvement in drug resistance	Indirect evidence for involvement in drug resistance
Chlorambucil	Bleomycin
Melphalan	Hepsulfam
Nitrogen mustard	Mitomycin C
Phosphoramidate mustard	Adriamycin
Acrolein	Cisplatin
BCNU	Carboplatin
Hydroxyalkenals	
Ethacrinic acid	
Steroids	

According to reference <sup>27</sup>

GST imparts a small but significant (and clinically relevant) increase in resistance to cisplatin (GST mu), doxorubicin (GST pi) or chlorambucil and melphalan (GST alpha).

### Glutathione peroxidase

Glutathione peroxidase catalyzes the reduction of potentially toxic peroxides to alcohols by oxidizing GSH to its disulfide form (GSSG). GSSG is returned to GSH with the concomitant oxidation of coenzyme NADPH to NADP<sup>+</sup>. GST enzyme can catalyze a selenium-independent GSH peroxidase activity leading to the detoxification of lipid and nucleic acid hydroperoxides. This redox cycle may play an essential role in protecting cells from damage of lipid peroxidation generated during normal metabolism or by redox recycling of many drugs.

Doxorubicin is one of the agents known to generate free radicals and peroxides. GST as well as the selenium -dependent enzyme GSH peroxidase can deactivate these metabolites through peroxidative mechanisms, resulting in decreased cytotoxicity. In tumor cells resistant to doxorubicin, increased levels of selen -dependent GSH peroxidase were found.<sup>33,34</sup>

### Metallothionein

Metallothioneins (MT) were first discovered as a family of inducible proteins involved in Zn<sup>2+</sup> and Cu<sup>2+</sup> homeostasis and in the detoxification of heavy metals.<sup>35,36</sup> They are evolutionary conserved low molecular weight intracellular proteins with unusually high level of cysteine content, that constitute the major fraction of the intracellular protein thiols.

Today is known that metallothioneins are a part of generalized cell response to environmental stress: the abundant nucleophilic thiol-rich groups in MT can react with many electrophilic toxins, participate in controlling the intracellular redox potential, and act as scavengers of oxygen radicals generated during the metabolism of xenobiotics. They can be induced by environmental stimuli such as epinephrine, glucocorticoids, thermal injury, cytokines, cyclic nucleotides, phorbol esters, UV light, etc., suggesting a protective function and a role in cell growth and proliferation.<sup>35,36</sup>

Metallothioneins are attractive candidates as modulators of cellular sensitivity to anticancer drugs. Elevated levels of MT have been observed in some malignant cells with acquired resistance to antineoplastic drugs, such as cisplatin.<sup>37-40</sup> Increases in intracellular MT by gene-transfer-produced resistance

to cisplatin, melphalan and chlorambucil, and less to doxorubicin and bleomycin<sup>38</sup> or N-methyl-N-nitro-N-nitrosoguanidine (MN-NG) and methyl nitrosourea (MNU).<sup>41</sup> In most MT overexpressing cell lines, however, induction of MT did not cause a parallel increase in resistance. Therefore, the resistance associated with MT overexpression was not due to direct binding of the drug to MT. The study of Kaina and co-workers suggest that MT may participate as a cofactor or regulatory element in the repair or tolerance of toxic alkylating drugs.<sup>41</sup>

Nevertheless, increases in MT do not always result in a phenotype that is less sensitive to the toxic effects of antineoplastic drugs.<sup>42</sup> Thus, the protective role of MT has been questioned. Recently, transgenic mice lacking functional MT have been produced by homologous recombination of disrupted MTI and II genes. The embryonic cells of these mice exhibit enhanced sensitivity to cisplatin, melphalan, bleomycin, cytarabine or MNNG, confirming the protective function of metallothioneins against cytotoxic drugs.<sup>43</sup>

### Gene amplification

One of the important mechanisms of drug resistance is gene amplification. The first observation of this phenomenon was noted by Biedler and Spengler. They found chromosome elongation in cultured hamster cells resistant to methotrexate (MTX) and called this extra DNA "homogeneously staining regions" (HSR).<sup>44</sup> Schimke and co-workers then showed that the extra DNA contains extra copies of the gene for the enzyme dihydrofolate reductase (DHFR), explaining the increased enzyme levels in the resistant cell.<sup>45,46</sup> The amplified DNA may either be present in chromosomes as HSRs or free, as minute chromatin particles usually present in metaphase spreads as pair minutes, called double minutes (DM).

After the initial demonstration that cells can overcome the MTX inhibition of DHFR by overproducing the enzyme by means of gene amplification, numerous other examples of this mechanism have been reported: for MDR,<sup>2,4</sup> for metallothioneins<sup>35,36</sup> etc.

### DNA repair

The resistance to some cytotoxic drugs can be caused by enhanced ability of cells to repair the DNA induced damage or to tolerate their presence. One of the most studied phenomena in this respect is resistance to cisplatin.

It has been well established that cisplatin binds to DNA and that these adducts contribute to cellular toxicity. In a number of cisplatin resistant cell lines, an enhanced repair of DNA lesions has been demonstrated.<sup>21,22</sup> Thus, Eastman and Schulte provided direct evidence for increased repair showing that the predominant lesions, cis-GG adducts, were more rapidly removed from resistant than sensitive cells.<sup>47</sup> These resistant L1210 cells can also reactivate a cisplatin-damage plasmid more readily than sensitive parental cells.<sup>48</sup> However, a correlation of repair activity with drug-resistance has not always been demonstrated: L1210 cells with 100-fold resistance to cisplatin, removed cis-GG intra-strand adducts only slightly better than 20-fold resistant cells.<sup>47</sup>

Repair of platinum damage in very specific regions of the genome is a possible characteristic of enhanced repair in resistant cells. If only active genes are more efficiently repaired in resistant cells, then it is not likely that a significant change in overall platination levels or repair rates will occur. Enhanced gene-specific repair could explain some of the controversial results found in such investigations. While preferential repair of the interstrand cross-link in active versus

inactive regions was not found in Chinese hamster ovary cells,<sup>49</sup> it was demonstrated in resistant human ovarian 2008 cells.<sup>50</sup>

It was observed that some cisplatin-resistant cell may have higher DNA platination than parental cells,<sup>51</sup> or may tolerate several fold more platinum on their DNA at equitoxic concentrations as sensitive cells.<sup>52,53</sup> Considering these facts, the concept of enhanced tolerance to DNA damage was suggested as a potential mechanism of resistance. However, the basis of this phenomenon is not well understood.

Several groups have described DNA-binding proteins that retard the mobility of cisplatin-damaged DNA fragments in non-denaturing polyacrylamide gels. It has been hypothesized that these proteins are either involved in DNA repair by shielding adducts from repair, or are involved in transcription.<sup>54</sup> A number of cisplatin-resistant cells have been investigated for changes in these DNA damage-recognition proteins.<sup>22</sup> However, no obvious correlation between the expression of DNA damage-recognition proteins and resistance to cisplatin was found.

Some of the recent papers suggest that resistance to DNA damage can be acquired via the loss of DNA mismatched repair activity. The DNA mismatch repair system acts after DNA replication and corrects non-Watson-Crick base pair and other replication errors. Human cells lacking mismatch repair activity have high spontaneous mutation rates. Also, they may be resistant to certain cytostatics, such as etoposide,<sup>55</sup> cisplatin<sup>56</sup> or N-methyl-N-nitro-N-nitrosoguanidine.<sup>57</sup>

### DNA topoisomerase

Besides MDR, some resistant cell lines exhibit atypical multidrug resistance (at-MDR). At-MDR is distinguished from the MDR in the following ways: a) lack of cross-resistance to the *Vinca* alkaloids,<sup>58</sup> b) absence of a drug

accumulation defect,<sup>58</sup> c) relative insensitivity to modulation of resistance by verapamil or chloroquine typical inhibitors of P-glycoprotein,<sup>59</sup> and d) lack of overexpression of the MDR1 gene or its product, Pgp.<sup>59</sup>

At-MDR involves altered activity of topoisomerases II. Topoisomerases II are enzymes that catalyze changes in the secondary and tertiary structures of DNA. They are necessary for replication, recombination and transcription, as well as in mitotic chromosome condensation and segregation. Topoisomerases II act via introduction of a transient double-stranded break in one segment of a DNA molecule through which a second DNA duplex is passed before religation of the break.<sup>60</sup>

The levels of these enzymes are markedly higher in exponentially growing than in quiescent cell lines. Two distinct forms of topoisomerase II exist in human cells, termed  $\alpha$  (170 kDa form) and  $\beta$  (180 kDa form).<sup>61</sup> They differ not only in molecular weight but also in their patterns of expression and their apparent sensitivity to anticancer drugs.<sup>62</sup> In cell lines the expression of the  $\alpha$  isoform has been shown to be strictly proliferation dependent, whereas the  $\beta$  isoform is presented in both dividing and non-dividing cells.

There are some inhibitors of topoisomerase II (doxorubicin, epirubicin, mitoxantrone, etoposide, teniposide) that trap the "cleavable complex" resulting in increased DNA scissions and inhibition of rejoining.<sup>60,63,64</sup> These protein-associated DNA lesions are directly toxic to cells. The cells with a high level of topoisomerase II are generally more sensitive to inhibitors than cells with a low level of these enzymes.

There is a number of rodent and human tumor cells lines in which resistance to topoisomerase II inhibitors are connected with decreased level of the topoisomerase II  $\alpha$  and/or  $\beta$ . The resistance mechanisms appear to be the result of a decrease in the activity of topoisomerase II.<sup>63-68</sup>

Beside topoisomerase II, drug resistance may involve the altered activity of topoisomerase I. Topoisomerase I is an enzyme abundant in actively transcribing gene regions. It has important role in DNA replication and elongation step of transcription. Contrary to topoisomerase II, topoisomerase I introduce a transient single-stranded nick in DNA and is ATP independent. Several cytostatics, such as camptothecins and actinomycin D are the poisons of topoisomerase I.<sup>60,63,64</sup> Drug induced accumulation of topoisomerase I-DNA cleavable complex is directly proportional to drug cytotoxicity and anti-tumor activity. Resistance to topoisomerase I inhibitors involves altered activity of this enzyme, that may be caused by mutation(s) in the gene coding for topoisomerase I.<sup>69</sup>

### **Oncogenes and tumor suppresser genes: signal transduction pathway and apoptosis**

In last few years interest has been focused on oncogenes and their role in drug-resistance. The direct evidence that oncogenes can be involved in drug-resistance came from transfection studies. The transfection of murine NIH3T3 cells<sup>70,71</sup> or kerytocytes<sup>72</sup> with *ras* oncogene resulted in resistance to cisplatin. *Ras* oncogene may induce resistance to doxorubicin as well.<sup>73</sup> Moreover it was found that the degree of cisplatin resistance correlated directly with the level of *c-myc* expression,<sup>74,75</sup> while the re-establishment of the normal level of *c-myc* transcription restored original sensitivity.<sup>74</sup> *C-myc* oncogene was also involved in resistance to methotrexate.<sup>76</sup> Using ribosome mediated cleavage of *c-fos* mRNA, the role of *c-fos* oncogene in resistance to cisplatin was proved.<sup>77</sup> Resistance to cisplatin was achieved by the transfection of *src* oncogene as well.<sup>78</sup>

The mechanisms by which oncogenes cause drug-resistance is not quite clear.<sup>79</sup> It has been suggested that *c-myc* oncogene

binds to DNA, and thus directly or indirectly regulates a process of DNA repair.<sup>74</sup> *Ras* oncogene might induce resistance by regulating the expression of other genes involved in the protection of cell against cytostatics. It was shown for glutathione transferase pi,<sup>80</sup> topoisomerase II,<sup>81</sup> *c-jun*,<sup>82</sup> glutathione,<sup>83</sup> MDR,<sup>84</sup> or altered membrane potential.<sup>85</sup> Scanlon hypothesized that *fos* expression is the trigger that causes the resistance response (primary DNA reparability, as indicated by DNA polymerase  $\alpha$ , DNA polymerase  $\beta$ , thymidilate synthase, DHFR and topoisomerase I expression). Consistent with this concept is the observation that transfection of sensitive cells with *c-fos* generated ethold resistance to cisplatin,<sup>77</sup> while attenuation of the elevated *c-fos* expression returned the cisplatin toxicity to that of parent population. Another oncogene, mutated *p53*, may confer resistance to many hydrophobic drugs by stimulating specifically MDR1 promoter.<sup>84</sup>

It must be mentioned, however, that not always an increased expression of *ras*, *myc* or other oncogenes caused an increased resistance to cytostatics.<sup>75,86-88</sup>

In many cases the cellular damage caused by active doses of drug is not sufficient to explain the observed toxicity. Therefore, it is possible that some determinants of inherent drug sensitivity and resistance may be independent of those which involve the formation of the drug-target complex and its immediate biochemical sequel, such as commitment to cell death. Cell death is activated by natural control processes whose function is to allow repair of low level damage to DNA while eliminating those cells in which repair is not possible. There are two modes of cell death: apoptosis and necrosis. They differ morphologically and biochemically. Necrosis is associated with cell swelling, rupture of membranes and dissolution of organized structure. That is a consequence of the loss of osmoregulation. DNA degradation occurs at



a late stage. In contrast, in apoptosis internucleosomal cleavage of genomic DNA and chromatin condensation precedes the loss of membrane integrity (Figure 2). Necrosis mostly results from a major cell insult such as that caused by serious mechanical, ischemic, or toxic damage. Apoptosis generally occurs as a response to less severe injury and is also involved in the development and remodeling of normal tissue.<sup>89,90</sup>

Apoptosis induces a wide variety of cell stresses and cytotoxic chemicals,<sup>89,90</sup> among them anticancer drugs.<sup>91-94</sup> Deregulation of normally integrated cell cycle progression appears a central signalling event in most forms of apoptosis.<sup>90</sup>

Apoptosis is a highly conserved active mechanism that requires the expression of several specific genes. Also their exact function is not quite understood, certain genes have been proposed as positive (*p53*, *c-fos*, *c-myc*, interleukin-1 converting enzyme etc.) or negative regulatory elements (*bcl-2* or glutathione redox cycle). They induce or prevent the onset of apoptosis.<sup>95-103</sup> Among them, *p53* and *bcl-2* are the most important and most studied.

*p53* protein can function as a genetic switch capable of activating  $G_1$  arrest, resulting in the repair of DNA damage.<sup>94</sup> Also, it is


required for efficient activation of apoptosis following irradiation or treatment with chemicals. Loss of *p53* function has been reported to increase resistance of tumor cells to a variety of cytotoxic drugs.<sup>95,96</sup> Recently it was shown that cells with mutated *p53* gene display perturbed  $G_1$  arrest or apoptosis. This defect appears to reduce the sensitivity to DNA-damaging agents, suggesting that inhibition of apoptosis may represent a mechanism by which tumor cells may acquire drug-resistance.<sup>95,96</sup> By transfer of normal *p53* into *p53*-defective non-small cell cancer line, an important increase in sensitivity to cisplatin was determined, which was related to the promotion of apoptosis.<sup>97</sup> However, the paper recently published by Wosikowski *et al.* suggests that alterations in *p53* gene status or protein functions are not critical for the development of multidrug resistance.<sup>98</sup>

On the other hand, Bcl-2 protein inhibits apoptosis<sup>99,100</sup> and increases cell resistance to drugs.<sup>101</sup> Recently, *bcl-2* related gene products have been reported. One of them, Bax, homodimerizes as well as heterodimerizes with Bcl-2 protein. The Bcl-2:Bax ratio may determine survival or death after an apoptotic stimulus.<sup>102</sup>

Therefore, oncogenes and tumor suppressor genes may be involved in drug resistance in two ways: by increasing the level of protective molecules in cells or by inhibiting apoptosis.

### Other factors

In doxorubicin treated cells an altered pattern of intracellular drug distribution was observed. The initial accumulation of drug in perinuclear location was followed by the development of a punctate pattern of the drug scattered throughout the cytoplasm. This pattern was suggestive of a process of drug sequestration, possibly followed by vesicle transport. In resistant cells, alteration in



**Figure 2.** HeLa cells obtained 48 hours after a 1-hour treatment with 150  $\mu$ M cisplatin. Apoptotic cells showed typical chromatin condensation, fragmented nuclei and cellular shrinkage (arrowhead), while intact nuclei exhibit "mottled" fluorescence. From reference<sup>91</sup>.

the intracellular drug distribution was accompanied by a decrease in nuclear *versus* cytoplasm drug ratio.<sup>104,105</sup>

There is more and more evidence, that drug resistance is a multifactorial phenomenon (only for very low doses of the drug a single mechanism can be involved in drug-resistance. Thus, for instance, in cells resistant to cisplatin altered drug accumulation, increased levels of glutathione and related enzymes, metallothioneins, increased repair and altered expression of oncogenes could be observed.<sup>21,22,39,40</sup> In methotrexate resistant cells, decreased uptake of this drug, decreased polyglutamation, decreased affinity to DHFR and increased levels of target enzyme are the most common cause of drug resistance to MTX.<sup>106</sup> It should be mentioned, however, that all of these mechanisms need not be induced in drug resistant cells. So, in cisplatin resistant human laryngeal carcinoma cells only decreased platinum accumulation was connected with resistance to cisplatin, while no alteration in oncogene expression, no involvement of glutathione, glutathione transferase or metallothioneins was determined.<sup>40,87</sup>

Due to induction of several protective molecular mechanisms, resistant cells obtained after treatment with a single drug, can become resistant to various unrelated drugs (Table 4). The schedule of drug-resistance development can also influence the resistance pattern. Even with the same treatment schedule, clones with different cross-resistance patterns occur.<sup>109</sup>

It is generally accepted that the resistance to drugs can be induced by treatment with chemicals. However, in last several years it became obvious that also ionizing irradiation can induce drug resistance in irradiated cells<sup>110-114</sup> by the same mechanisms that are involved in resistance development induced by cytostatics.<sup>112,114-120</sup> This fact, if supported *in vivo*, and specially in clinic, is of the utmost importance for the patients. Namely, if irradiation precedes chemotherapy, it can reduce the success of combined therapy.

In conclusion, drug resistance is a complex, multifactorial phenomenon, which may involve decreased intracellular drug accumulation, increased detoxification, increased DNA repair, decreased activity of topoisomerases, gene amplification, altered onco-

**Table 4.** Drug sensitivity pattern of resistant cell lines

Cell line	Drug used for resistance development	Treatment schedule	Resistant to	Sensitive to
Laryngeal carcinoma <sup>1</sup>	vincristine	acute continuous	DOX, MTX DOX, MTX, 5-FU	CDDP CDDP
Cervical carcinoma <sup>2</sup>	cisplatin	acute continuous	VCR, DOX, ETO, MTX, 5-FU VCR, MTX	
Laryngeal carcinoma <sup>3</sup>	cisplatin	acute continuous	VCR, MMC VCR, MMC, 5-FU	ETO, DOX
Breast adeno-carcinoma <sup>4</sup>		doxorubicin	continuous	VCR, VBL, CDDP, CBDCA, (MMC, 5-FU)*

<sup>1</sup> reference 107, <sup>2</sup> reference 39, <sup>3</sup> reference 108, <sup>4</sup> reference 88.

\* Significant resistance only at higher doses.

Acute = 1 hour treatment; continuous = 24 hours treatment

VCR= vincristine, VBL= vinblastine, DOX = doxorubicin, ETO = etoposide, MTX = methotrexate, 5-FU = 5-fluorouracil, CDDP= cisplatin, CBDCA= carboplatin, MMC= mitomycin C.

gene and tumor suppressor gene expression, as well as inhibition of apoptosis. Resistance pattern of anticancer drugs is determined by the a) genotype of the cells, b) genotoxic agent involved in resistance development, and c) treatment schedule. The complexity of drug-resistance mechanisms, as well as sometimes conflicting experimental data suggest the need to continue such investigation and clarify the cascade of events involved in this process.

## References

- Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remission in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl - glutamic acid (aminopterin). *N Engl J Med* 1948; **238**: 787-93
- Endicott JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. *Ann Rev Biochem* 1989; **58**: 137-71.
- Kayne SB. Multidrug resistance. *Oncology Today* 1990; **2**: 4-7.
- Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. *Ann Rev Biochem* 1993; **62**: 385-429.
- Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin and vinblastine. *Proc Natl Acad USA* 1987; **84**: 3004-8.
- Gerlach JH, Endicott JA, Jurakna PE, Henderson G, Sarangi F, Deuchars KL, Ling V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. *Nature* 1986; **324**: 485-9.
- Nielsen D, Skovgaard T. P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. *Biochem Biophys Acta* 1992; **1139**: 169-83.
- Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science* (Washington DC) 1992; **258**: 1650-4.
- Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP. *Eur J Cancer* 1996; **32A**: 945-57.
- Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. *Cancer Res* 1994; **54**: 357-61.
- Slapak CA, Mizunuma N, Kufe DW. Expression of the multidrug resistance-associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. *Blood* 1994; **84**: 3113-21.
- Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SPC, Sehested M. Sequential coexpression of the multidrug resistance genes *MRP* and *mdr1* and their products in VP-16 (Etoposide)-selected H69 small cell lung cancer cells. *Cancer Res* 1995; **55**: 459-62.
- Goldenberg GJ, Vanstone CL, Israels LG, Ilse D, Bihler I. Evidence of a transport carrier of nitrogen mustard-sensitive and -resistant L5178Y lymphoblasts. *Cancer Res* 1970; **30**: 2258-91.
- Sirotnak FM, Maccio DM, Kelleher LE, Goutas LJ. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L-1210 clonal cell lines derived in vivo. *Cancer Res* 1981; **41**: 4447-52.
- Shionoya S, Lu Y, Scanlon KJ. Properties of amino acid transport system in K 562 cells sensitive and resistant to cis-diamminedichloroplatinum(II). *Cancer Res* 1986; **46**: 3445-8.
- Meister A. Glutathione, ascorbate, and cellular protection. *Cancer Res* 1994; **54**: 1969s-75s.
- Morris PE, Gordon RB. Significance of glutathione in lung disease and implications for therapy. *Amer J Med Sci* 1994; **307**: 119-27.
- Suzakake K, Petro BJ, Vistica DT. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. *Biochem Pharmacol* 1982; **31**: 121-4.
- Mitchell JB, Russo A. The role of glutathione in radiation and drug induced cytotoxicity. *Br J Cancer* 1987; **55**: 96-104.
- Ahmad S, Okine L, Le B, Najarian P, Vistica DT. Elevation of glutathione in phenylalanine mustard-resistant murine L1210 leukemia cells. *J Biol Chem* 1987; **262**: 15048-53.
- Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Cisplatin resistance in human cancers. *Pharmac Ther* 1991; **52**: 385-406.
- Andrew PA. Mechanisms of acquired resistance to cisplatin. In: *Anticancer Drug Resistance: Advances in Molecular and clinical Research* (Goldstein LJ and Ozols RF, eds.) Kluwer Academic Publishers, 1994, 217-48.
- Lee FYF, Siemann DW. Isolation by flow cytometry of a human ovarian tumor cell subpopulation exhibiting a high glutathione content phenotype

- and increased resistance to Adriamycin. *Int J Radiat Oncol Biol Phys* 1989; **16**: 1315-9.
24. Lai GM, Ozols RF, Young RC, Hamilton TC. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. *J Nat Cancer Inst* 1989; **81**: 535-9.
  25. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, Mc Koy WM, Young RC, Ozols RF. Augmentation of Adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and drug-sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. *Biochem Pharmacol* 1985; **34**: 2583-6.
  26. Barranco SC, Townsend CM Jr, Weintraub B, Beasley EG, McLean KK, Shaeffer J, Liu NH, Schellenberg K. Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatment with melphalan in vitro. *Cancer Res* 1990; **50**: 3614-8.
  27. Tew K. Glutathione-associated enzymes in anticancer drug resistance. *Cancer Res* 1994; **54**: 4313-20.
  28. Waxman DJ. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy- A review. *Cancer Res* 1990; **50**: 6449-54.
  29. Gulick AM, Fahl WE. Mammalian glutathione S-transferase: regulation of an enzyme system to achieve chemotherapeutic efficacy. *Pharmacol Ther* 1995; **66**: 237-57.
  30. Moscow JA, Fairchild CR, Madden MJ, Ransom DT, Wieand HS, O'Brien EE, Poplack DG, Cossman J, Myers CE, Cowan KH. Expression of anionic glutathione S-transferase and P-glycoprotein genes in human tissues and tumors. *Cancer Res* 1989; **49**: 1422-8.
  31. Howie AF, Forrester LM, Glancey MJ, Schlager JJ, Powis G, Beckett GJ, Hayes JD, Wolf CR. Glutathione S-transferase and glutathione peroxidase expression in normal and tumor human tissues. *Carcinogenesis* 1990; **11**: 451-8.
  32. Puchalski RB, Fahl WE. Expression of recombinant glutathione transferase p, Ya, or Yb confers resistance to alkylating agents. *Proc Natl Acad Sci USA* 1990; **87**: 2443-7.
  33. Batist G, Tople A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug resistant breast cancer cells. *J Biol Chem* 1986; **33**: 15544-9.
  34. Kramer RA, Zakher J, Kim G. Role of glutathione redox cycle in acquired and de novo multidrug resistance. *Science* 1988; **241**: 694-7.
  35. Hamer DH. Metallothionein <sup>1,2</sup>. *Ann Rev Biochem* 1986; **55**: 913-51.
  36. Moffatt P, Denizeau F. Metallothionein in physiological and physiopathological processes. *Drug Metabol Rev* 1997; **29**: 261-307.
  37. Bakka A, Endersen L, Johnsen ABS, Edminson PD, Rugstad HE. Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. *Toxicol Appl Pharmacol* 1981; **61**: 215-26.
  38. Kelley SL, Basu A, Tiecher B, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. *Science* 1988; **241**: 1813-5.
  39. Osmak M, Eljuga D. The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin. *Res Exp Med* 1993; **193**: 389-96.
  40. Beketić-Orešković L, Osmak M, Jakšić M. Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): Mechanisms involved in resistance. *Neoplasma* 1994; **41**: 163-9.
  41. Kaina B, Lohrer H, Karin M, Herrlich P. Overexpressed human metallothionein IIA gene protects Chinese hamster ovary cells from killing by alkylating agents. *Proc Natl Acad Sci USA* 1990; **87**: 2710-4.
  42. Schilder RJ, Hall L, Monks A, Fornace AJ Jr, Ozols RF, Fojo AT, Hamilton TC. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. *Int J Cancer* 1990; **45**: 416-22.
  43. Kondo Y, Woo ES, Michalska AE, Choo KHA, Lazo JS. Metallothionein null cells have increased sensitivity to anticancer drugs. *Cancer Res* 1995; **55**: 2021-3.
  44. Biedler JL, Spengler BA. Metaphase chromosome anomaly association with drug resistance and cell specific products. *Science* 1976; **191**: 185-7.
  45. Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. *J Biol Chem* 1978; **253**: 1357-70.
  46. Schimke RT. Gene amplification in cultured animal cells. *Cell* 1984; **37**: 705-13.
  47. Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to DNA cis-diamminedichloroplatinum(II). *Biochemistry* 1988; **27**: 4730-4.
  48. Sheibani N, Jennerwein MM, Eastman A. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. *Biochemistry* 1989; **28**: 3120-4.
  49. Jones JC, Zhen W, Reed E, Parker RJ, Sancar A, Bohr VA. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. *J Biol Chem* 1991; **266**: 7101-7.
  50. Zhen W, Link CJ Jr, O'Connor PM, Reed E, Parker

- R, Howell SB, Bohr VA. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. *Mol Cell Biol* 1992; **12**: 3689-98.
51. Strandberg MC, Bresnick E, Eastman A. The significance of DNA cross-linking to *cis*-diaminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells. *Chem Biol Interact* 1982; **39**: 169-80.
  52. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. *J Clin Invest* 1991; **87**: 772-7.
  53. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. *Cancer Res* 1997; **57**: 850-6.
  54. Donahue BA, Augot M, Bellon SF, Treiber DK, Toney JH, Lippard SJ. Characterization of a DNA damage-recognition protein from mammalian cells that binds to intra-strand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. *Biochemistry* 1990; **29**: 5872-80.
  55. De las Alas MM, Aebi S, Fink D, Howell SB, Los G. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. *J Natl Cancer Inst* 1997; **89**: 1537-41.
  56. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL, Howell SB. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. *Cancer Res* 1997; **57**: 1941-5.
  57. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, Boland CR, Rarrett JC, Kunkel TA. Correction of hypermutability, N-methyl-N-nitro-N-nitroso-guanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. *Cancer Res* 1997; **57**: 3949-55.
  58. Danks MK, Yalowich JC, Beck WT. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). *Cancer Res* 1987; **47**: 1297-301.
  59. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM. Pharmacological, molecular and cytogenetic analysis of "typical" multidrug-resistant human leukemic cells. *Cancer Res* 1987; **47**: 5455-60.
  60. Liu LF. DNA topoisomerase poisons as antitumor drugs. *Annu Rev Biochem* 1989; **58**: 351-75.
  61. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. *Biochem* 1989; **28**: 8154-60.
  62. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cycle-dependent differences in expression of the 170 kDa and 180 kDa forms of topoisomerase II in NIH 3T3 cells. *Cell Growth Different* 1991; **2**: 209-14.
  63. Smith PJ. Topoisomerase inhibitors: new twists to anticancer drug action. *Oncology Today* 1991; **3**: 4-9.
  64. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy. *Cancer Chemother Pharmacol* 1993; **32**: 103-8.
  65. Glisson B, Gupta R, Smallwood-Kent S, Ross W. Characterisation of acquired epipodophyllotoxins resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. *Cancer Res* 1986; **46**: 1934-8.
  66. Davies SM, Robson CN, Davies SL, Hickson ID. Nuclear topoisomerase levels correlate with sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. *J Biol Chem* 1988; **263**: 17724-72.
  67. Deffie AM, Bosman DJ, Goldenberg GJ. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells. *Cancer Res* 1989; **49**: 6879-82.
  68. Beck WT, Danks MK, Wolverton JS, Kim R, Chen M. Drug resistance associated with altered DNA topoisomerase II. *Adv Enzyme Regul* 1993; **33**: 113-27.
  69. Wang LF, Ting CY, Lo CK, Su JS, Mickley LA, Fojo AT, Whang-Peng J, Hwang J. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. *Cancer Res* 1997; **57**: 1516-22.
  70. Sklar M. Increased resistance to *cis*-diaminedichloroplatinum(II) in NIH3T3 cells transformed by *ras* oncogenes. *Cancer Res* 1988; **48**: 793-7.
  71. Ishonishi S, Hom DK, Thiebaut FB, Mann SC, Andrews PA, Basu A, Laso JS, Eastman A, Howell SB. Expression of the c-Ha-ras oncogene in mouse NIH3T3 cells induces resistance to cisplatin. *Cancer Res* 1991; **51**: 5903-9.
  72. Sanchez-Prieto R, Vargas JA, Carnero A, Marchetti E, Romero J, Durantez A, Lacal JC, Cajal SR. Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes. *Int J Cancer* 1995; **60**: 235-43.
  73. Peters GJ, Wets M, Keepers YPAM, Oskam R, Van Ark-Otte J, Noordhuis P, Smid K, Pinedo HM. Transformation of mouse fibroblasts with the oncogenes *H-ras* or *trk* is associated with pronounced changes in drug sensitivity and metabolism. *Int J Cancer* 1993; **54**: 450-5.
  74. Sklar MD, Prochownik EV. Modulation of cisplatin resistance in Friend erythroleukemia cells by *c-myc*. *Cancer Res* 1991; **51**: 2118-23.

75. Niimi SK, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, Terada M, Saijo N. Resistance to anticancer drugs in NIH3T3 cells transformed with *c-myc* and/or *c-Ha-ras* genes. *Br J Cancer* 1991; **63**: 237-41.
76. Denis NA, Kitzis A, Kruh J, Dautry F, Corcos D. Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by *c-myc*. *Oncogene* 1991; **6**: 1433-57.
77. Scanlon KJ, Jiao L, Funato T, Wang W, Tone T, Rossi JJ, Kashani-Sabet M. Ribozyme mediated cleavage of *c-fos* mRNA reduces gene expression of DNA synthesis enzymes and metallothioneins. *Proc Natl Acad Sci USA* 1991; **88**: 10591-5.
78. Masumoto N, Nakano S. Cell signaling and CDDP resistance. *Gan To Kagaku Ryoho* 1997; **24**: 424-30.
79. El-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. *Curr Opin Oncol* 1997; **9**: 79-87.
80. Burt RK, Garfield S, Johnson K, Thorgerirsson SS. Transformation of rat liver epithelial cells with *v-Ha-ras* or *v-raf* causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals. *Carcinogenesis* 1988; **9**: 2329-32.
81. Woessner RD, Chung TDY, Hofmann GA, Matern MR, Mirabelli CK, Drake FH, Johnson RK. Differences between normal and *ras*-transformed NIH 3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II. *Cancer Res* 1990; **50**: 2901-8.
82. Binetruy B, Smeal T, Karin M. *Ha-ras* augments *c-jun* activity and stimulates phosphorylation of its active domain. *Nature* 1991; **351**: 122-7.
83. Thrall BD, Meadows GG. Induction of glutathione content in murine melanocytes after transformation with *c-Ha-ras* oncogene. *Carcinogenesis* 1991; **12**: 1319-23.
84. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human *mdr1* gene by *ras* and *p53*. *Science* 1992; **255**: 459-62.
85. Spalletticernia D, Dagnano I, Salvatore C, Portella G, Zupi G, Vecchio G, Lancetti P. Transformation by *v-ras* oncogene correlates with an increased drug resistance in an epithelial thyroid cell system. *Int J Oncol* 1995; **6**: 647-54.
86. Toffoli G, Viel A, Tumiotto L, Buttazzi P, Biscontin G, Boiocchi M. Sensitivity pattern of normal and *H-ras* transformed NIH3T3 fibroblasts to antineoplastic drugs. *Tumori* 1989; **75**: 423-8.
87. Osmak M, Beketić-Orešković L, Matulić M, Sorić J. Resistance of human larynx carcinoma cells to cisplatin, gamma irradiation and methotrexate do not involve overexpression of *c-myc* or *c-Ki-ras* oncogenes. *Mutat Res* 1993; **303**: 113-20.
88. Osmak M, Kapitanović S, Vrhovec I, Beketić-Orešković L, Jernej B, Eljuga D, Škrk J. Characterization of human breast adenocarcinoma SK-BR-3 cells resistant to doxorubicin. *Neoplasma* 1997; **44**: 157-62.
89. Vaux DL. Toward an understanding of the molecular mechanisms of physiological cell death. *Proc Natl Acad Sci USA* 1993; **90**: 786-9.
90. Smets LA. Programmed cell death (apoptosis) and response to anti-cancer drugs. *Anti-Cancer Drugs* 1994; **5**: 3-9.
91. Osmak M, Abramić M, Brozović A, Hadžija M. Cell response to low repeated doses of ionising radiation: inhibition of apoptosis in cisplatin treated human cells. *Period Biol* 1997; **99**: 329-33.
92. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. *Biochem Pharmacol* 1990; **40**: 2353-62.
93. Evans DL, Dive C 1993 Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. *Cancer Res* 1993; **55**: 2133-9.
94. Lane DP. P53, guardian of the genome. *Nature* 1992; **358**: 15-16.
95. Lowe SW, Ruley HE, Jacks T, Houseman DE p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. *Cell* 1993; **74**: 957-67.
96. Anthoney DA, McIlwrath AJ, Gallanger WM, Edlin ARM, Brown R. Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells. *Cancer Res* 1996; **56**: 1374-81.
97. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W-W, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus - mediated transfer of the wild-type p53 gene. *Cancer Res* 1994; **54**: 2287-91.
98. Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JTM, Gudas JM, Bates SE. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. *Cell Growth Different* 1995; **6**: 1395- 403.
99. Hockenbery DM, Nunez G, Millman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* 1990; **348**: 334-6.
100. Reed JC. Bcl-2 and regulation of programmed cell death. *J Cell Biol* 1994; **124**: 1-6.
101. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a human leukemia cell line. *Blood* 1993; **81**: 151-7.
102. Yin X-M, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. *Nature* 1994; **369**: 609-19.

103. Zhao R, Rabo YB, Egyhazi S, Anderson A, Edgren MR, Linder S, Hansson J. Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and drug-resistant daughter cell-line. *Anti-Cancer Drugs* 1995; **6**: 657-68.
104. Schuurhuis GJ, Broxterman HJ, de Lange JHM, Pinedo HM, van Heijningen THM, Kuiper CM, Scheffer GL, Scheper RJ, van Kalken CK, Baak JAP, Lankelma J. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. *Br J Cancer* 1991; **64**: 857-61.
105. Breuninger L, Saptarshi P, Gaughan K, Miki T, Chan A, Aaronson SA, Kruh GD. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. *Cancer Res* 1995; **55**: 5342-27.
106. Borst P. Genetic mechanisms of drug resistance. *Acta Oncol* 1991; **4**: 87-105.
107. Osmak M, Eljuga D. The response of two vincristine resistant human larynx carcinoma cell clones to chemotherapeutic drugs. *Radiol Oncol* 1992; **26**: 140 - 4.
108. Beketić-Orešković L, Osmak M. Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): Cross-resistance pattern. *Neoplasma* 1994; **41**: 171-6.
109. Osmak M, Bizjak L, Jernej B, Kapitanović S. Characterization of carboplatin-resistant sublines derived from human larynx carcinoma cells. *Mutat Res* 1995; **347**: 141-50.
110. Osmak M. Repeated doses of gamma rays induce resistance to N-methyl-N-nitro-N-nitrosoguanidine in Chinese hamster cells. *Radiat Res* 1988; **115**: 609-16.
111. Osmak M, Perović S. Multiple fractions of gamma rays induced resistance to cis-dichlorodiammineplatinum (II) and methotrexate in human HeLa cells. *Int J Radiation Oncology Biol Phys* 1989; **16**: 1537-41.
112. Hill BT Interactions between antitumor agents and radiation and the expression of resistance. *Cancer Treatment Reviews* 1991; **18**: 149-90.
113. Osmak M, Horvat D. Chromosomal analysis of Chinese hamster V79 cells exposed to multiple gamma-ray fractions: induction of adaptive response to mitomycin C. *Mutat Res* 1992; **282**: 259-63.
114. Osmak M, Kapitanović S, Miljanić S. Low doses of gamma rays can induce the expression of *mdr* gene. *Mutat Res* 1994; **324**: 35-41.
115. Mattern J, Effert T, Volm M. Overexpression of P-glycoprotein in human lung carcinoma xenografts after fractionated irradiation in vivo. *Radiat Res* 1991; **127**: 335-8.
116. Osmak M, Užarević B. Mechanisms involved in resistance of preirradiated Chinese hamster V79 cells to cytotoxic drugs are multifactorial. *Res Exp Med* 1991; **191**: 413-21.
117. Dempke WCM, Shellard SA, Hosking LK, Fichtinger-Schepmen AMJ, Hill BT. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation. *Carcinogenesis* 1992; **13**: 1209-15.
118. McClean S, Whelm RDT, Hosking LK, Hodges GM, Thompson FH, Meyers MB, Schuurhuis GJ, Hill BT Characterization of the P-glycoprotein over-expressing drug resistance phenotype exhibited by Chinese hamster ovary cells following their in-vitro exposure to fractionated X-irradiation. *Biochim Biophys Acta* 1993; **1177**: 117-26.
119. Osmak M. Multifactorial molecular mechanisms are involved in resistance of preirradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine. *Neoplasma* 1993; **440**: 97-101.
120. Osmak M, Matulić M, Sorić J. Multiple fractions of gamma rays do not induce overexpression of *c-myc* or *c-Ki-ras* oncogenes in human cervical carcinoma cells. *Neoplasma* 1993; **40**: 359-62.